Imexpharm Corp (IMP) - Total Assets
Based on the latest financial reports, Imexpharm Corp (IMP) holds total assets worth ₫2.95 Trillion VND (≈ $111.96 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Imexpharm Corp - Total Assets Trend (2019–2025)
This chart illustrates how Imexpharm Corp's total assets have evolved over time, based on quarterly financial data. Also see Imexpharm Corp (IMP) total market value for the company's overall valuation and market capitalisation.
Imexpharm Corp - Asset Composition Analysis
Current Asset Composition (December 2025)
Imexpharm Corp's total assets of ₫2.95 Trillion consist of 54.2% current assets and 45.8% non-current assets. Review how much debt does Imexpharm Corp carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (VND) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₫0.00 | 6.8% |
| Accounts Receivable | ₫327.75 Billion | 11.8% |
| Inventory | ₫677.72 Billion | 24.4% |
| Property, Plant & Equipment | ₫0.00 | 0.0% |
| Intangible Assets | ₫116.49 Billion | 4.2% |
| Goodwill | ₫0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Imexpharm Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Imexpharm Corp stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Imexpharm Corp's current assets represent 54.2% of total assets in 2025, an increase from 42.2% in 2019.
- Cash Position: Cash and equivalents constituted 6.8% of total assets in 2025, up from 4.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 3.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 24.4% of total assets.
Imexpharm Corp Competitors by Total Assets
Key competitors of Imexpharm Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥29.95 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
ASPEN PHAR.UN.ADR /1 O.N.
F:LDZU
|
Germany | €128.04 Billion |
Imexpharm Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.36 | 2.63 | 2.86 |
| Quick Ratio | 2.02 | 1.60 | 1.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₫1.18 Trillion | ₫1.06 Trillion | ₫609.27 Billion |
Imexpharm Corp - Advanced Valuation Insights
This section examines the relationship between Imexpharm Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.51 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 11.1% |
| Total Assets | ₫2.78 Trillion |
| Market Capitalization | $215.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values Imexpharm Corp's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Imexpharm Corp's assets grew by 11.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Imexpharm Corp (2019–2025)
The table below shows the annual total assets of Imexpharm Corp from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₫2.78 Trillion ≈ $105.72 Million |
+11.09% |
| 2024-12-31 | ₫2.50 Trillion ≈ $95.17 Million |
+4.69% |
| 2023-12-31 | ₫2.39 Trillion ≈ $90.90 Million |
+5.08% |
| 2022-12-31 | ₫2.28 Trillion ≈ $86.51 Million |
-0.77% |
| 2021-12-31 | ₫2.29 Trillion ≈ $87.18 Million |
+9.46% |
| 2020-12-31 | ₫2.10 Trillion ≈ $79.65 Million |
+13.50% |
| 2019-12-31 | ₫1.85 Trillion ≈ $70.18 Million |
-- |
About Imexpharm Corp
Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company's products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and mine… Read more